PubMed Central
Cure8 research brief
Why This Matters
Animal research shows a postbiotic from Enterococcus faecium altered gut barrier markers and the microbiome in chickens; this may be of scientific interest for gut microbiome and adjuvant research but does not imply benefit for people with IBD.
Who Should Pay Attention
Researchers studying the microbiome, postbiotics, vaccine adjuvants, and preclinical gut-health interventions; not directly for patients or clinicians treating human IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This is an animal (chicken) research study, not human IBD research. It examined postbiotic (cell-free) preparations delivered in drinking water to young chicks and measured gene expression, microbiome changes, and antibody responses after vaccination.
Reported findings include higher expression of mucin (MUC2), occludin (OCLN), IL-10 and other markers, and altered gut microbiota (more Enterococcus and Bifidobacterium) in the JB00008 group compared with controls.
Findings suggest JB00008 might support intestinal barrier-related markers and microbiota composition in chickens without affecting growth, and the authors propose potential use as a feed additive or vaccine adjuvant. These results do not demonstrate safety or efficacy in humans with IBD and cannot be directly translated to patient care.
Keep In Mind
This is a controlled study in broiler chickens (animal model) focused on vaccination and gut markers; it is not a human clinical trial. Results are preliminary and species-specific, so they should not be used to guide treatment decisions in people with IBD.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPubMed Central
JournalPLoS One
AuthorsLee, Seonju, Choi, Seojin, Park, Jongbin +2 more
Indexed viaPubMed Central
Source typeResearch repository record
PublishedJul 16, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cimicifuga foetida L. polysaccharide alleviates ulcerative colitis by inhibiting pyroptosis and regulating gut microbiota
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
Insights into the mechanism of treatment of ulcerative colitis with pre- and post-processed dried ginger through perspective of metabolomics and intestinal microbiomics research.
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...
Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...